ADVFN US – Market Content Editor

Lyell Immunopharma Inc. (NASDAQ:LYEL) gained 4.2% in premarket trading Monday after the company released encouraging new data from its cancer therapy programs. The biotech reported that its CAR T-cell candidate, rondecabtagene autoleucel (ronde-cel), achieved a 93% overall response rate and a 76% complete response rate in patients with large B-cell lymphoma treated in the third-line…

Structure Therapeutics Inc. ADR (NASDAQ:GPCR) soared 28.8% in Monday’s premarket trading after releasing strong topline results from its ACCESS clinical program evaluating aleniglipron, an oral GLP-1 receptor agonist being developed for obesity. In the Phase 2b ACCESS trial, the 120 mg dose produced a placebo-adjusted mean weight reduction of 11.3% (27.3 lbs) at 36 weeks.…

Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its acute myeloid leukemia (AML) vaccine candidate, EVX-04. At the American Society of Hematology Annual Meeting in Orlando, the company reported that EVX-04 generated robust T-cell activation and effectively suppressed tumor growth in preclinical models. EVX-04 is an off-the-shelf…

Cogent Biosciences Inc. (NASDAQ:COGT) surged 12.6% in Monday’s premarket session after unveiling encouraging top-line findings from APEX Part 2, its registration-directed Phase 2/3 study evaluating bezuclastinib in advanced systemic mastocytosis (AdvSM). The company reported a 57% objective response rate based on mIWG criteria and an 80% response rate per PPR criteria. Additionally, 89% of patients…

BioNTech SE (NASDAQ:BNTX) traded 3.1% higher in Monday’s premarket session after the company, alongside partner OncoC4, released encouraging survival data for its investigational lung cancer therapy, gotistobart. The selective Treg-modulating drug produced a marked survival advantage in patients with previously treated squamous non-small cell lung cancer (sqNSCLC) when compared with standard chemotherapy. With nearly 15…

Beam Therapeutics Inc. (NASDAQ:BEAM) saw its shares rise 1.7% in premarket trading Monday after releasing updated results from its BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) for sickle cell disease (SCD). The latest data, presented at the 67th American Society of Hematology Annual Meeting, showed mean fetal hemoglobin (HbF) induction above 60% along with…

Shares of Alx Oncology Holdings (NASDAQ:ALXO) jumped 12% in premarket trading Monday after the biotech reported encouraging Phase 2 results for its investigational therapy evorpacept. In the study, evorpacept was paired with the standard rituximab and lenalidomide (R2) regimen in previously untreated patients with indolent non-Hodgkin lymphoma (iNHL). The combination delivered complete responses in 92%…

Arcellx Inc. (NASDAQ:ACLX) rallied 13.6% in premarket trading Monday after releasing encouraging data from its pivotal Phase 2 iMMagine-1 trial evaluating anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. In the latest update, the company reported a 96% overall response rate and a 74% complete response/stringent complete response rate at a median…

Shares of Dyne Therapeutics (NASDAQ:DYN) gained 7% after the biotech unveiled encouraging topline findings from its Phase 1/2 DELIVER study evaluating Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD). According to the update, the trial’s Registrational Expansion Cohort achieved its main goal, delivering a statistically meaningful rise in dystrophin to 5.46% at six months versus baseline. Dyne…